Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
All India Institute of Medical Sciences, New Delhi |
---|---|
Information provided by: | All India Institute of Medical Sciences, New Delhi |
ClinicalTrials.gov Identifier: | NCT00624143 |
Hypothesis:Oral Voriconazole will be as effective as intravenous Amphotericin B as antifungal prophylaxis in induction of acute leukemia (ALL, AML) in pediatric patients, with less toxicity and more convenience.
Condition | Intervention | Phase |
---|---|---|
Pediatric Acute Leukemia Induction |
Drug: ORAL VORICONAZOLE and IV Amphotericin B |
Phase III |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Open Label, Parallel Assignment, Efficacy Study |
Official Title: | Oral Voriconazole vs IV Low Dose Amphotericin B for Primary Antifungal Prophylaxis in Pediatric Acute Leukemia Induction:A Prospective, Randomized, Clinical Trial. |
Estimated Enrollment: | 100 |
Study Start Date: | February 2008 |
Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Active Comparator
Oral Voriconazole
|
Drug: ORAL VORICONAZOLE and IV Amphotericin B
Oral Voriconazole will be given in dose of 6mg/kg 12 hourly on day1 then 4mg/kg 12 hourly daily or IV Amphotericin B 0.5 mg/kg/day weekly thrice till the completion of induction or recovery of ANC >1000/MM3 or development of fungal infection
|
2: Active Comparator
IV Amphotericin B
|
Drug: ORAL VORICONAZOLE and IV Amphotericin B
Oral Voriconazole will be given in dose of 6mg/kg 12 hourly on day1 then 4mg/kg 12 hourly daily or IV Amphotericin B 0.5 mg/kg/day weekly thrice till the completion of induction or recovery of ANC >1000/MM3 or development of fungal infection
|
Ages Eligible for Study: | up to 15 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Febrile patients with no pneumonia, systemic fungal infection and hemodynamically stable will be eligible for study.
Exclusion Criteria:
Contact: SAMEER BAKHSHI, MD | 91-11-26588153 | sambakh@hotmail.com |
India, Delhi | |
Institute Rotary Cancer Hospital, All India Institute of Medical Sciences | Recruiting |
New Delhi, Delhi, India, 110029 | |
Contact: SAMEER BAKHSHI, MD 91-11-26588153 sambakh@hotmail.com |
Principal Investigator: | SAMEER BAKHSHI, MD | Institute Rotary Cancer Hospital, All India Institute of Medical Sciences |
Responsible Party: | Dr.Sameer Bakhshi ( Dr. Sameer Bakhshi, Associate Professor, Medical Oncology, IRCH, AIIMS, New Delhi ) |
Study ID Numbers: | antifungal prophylaxis, Dr. SAMEER BAKHSHI |
Study First Received: | February 19, 2008 |
Last Updated: | February 19, 2008 |
ClinicalTrials.gov Identifier: | NCT00624143 History of Changes |
Health Authority: | India: Institutional Review Board |
Antifungal prophylaxis, acute leukemia induction, |
Abelcet Acute Disease Anti-Bacterial Agents Anti-Infective Agents Amphotericin B |
Leukemia Antifungal Agents Voriconazole Liposomal amphotericin B |
Acute Disease Abelcet Anti-Infective Agents Amphotericin B Disease Attributes Antiprotozoal Agents Neoplasms by Histologic Type Liposomal amphotericin B Pharmacologic Actions Anti-Bacterial Agents |
Leukemia Antiparasitic Agents Neoplasms Pathologic Processes Therapeutic Uses Antifungal Agents Voriconazole Antibiotics, Antifungal Amebicides |